// App-Quantinova.ai

5573.0 : Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC).

Researchers

Presenter

  • Phillip Lee Palmbos

Principal Investigators

  • Scott A. Tomlins

  • Stephanie Daignault

  • Neeraj Agarwal

  • Przemyslaw Twardowski

  • Alicia K. Morgans

  • William Kevin Kelly

  • Vivek Arora

  • Emmanuel S. Antonarakis

  • Javed Siddiqui

  • Dan Robinson

  • Karen E. Knudsen

  • Arul Chinnaiyan

  • Maha H. A. Hussain

Medical Centers

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • University of Michigan, Ann Arbor, MI

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • City of Hope, Duarte, CA

  • Northwestern University, Chicago, IL

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • Washington University in St Louis, St. Louis, MO

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Center for Translational Pathology, University of Michigan, Ann Arbor, MI

  • Kimmel Cancer Center Jefferson, Philadelphia, PA

  • Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Palbociclib

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02059213

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved